Table 3.
The diagnostic performance of markers for significant fibrosis and severe fibrosis in CHB
| AUROC | Cut‐off | Sensitivity (%) | Specificity (%) | PLR | NLR | PPV (%) | NPV (%) | |
|---|---|---|---|---|---|---|---|---|
| FIB‐4 | ||||||||
| S ≥ 2 | 0.683 | 1.13 | 81.1 | 55.3 | 1.82 | 0.34 | 30.9 | 92.2 |
| 1.45 | 58.5 | 70.2 | 1.96 | 0.59 | 32.6 | 87.3 | ||
| 3.25 | 7.5 | 95.8 | 1.80 | 0.96 | 30.8 | 80.8 | ||
| S ≥ 3 | 0.730 | 1.15 | 95.7 | 53.1 | 2.04 | 0.082 | 16.1 | 99.2 |
| APRI | ||||||||
| S ≥ 2 | 0.724 | 0.52 | 80.8 | 52.8 | 1.67 | 0.37 | 29.1 | 91.7 |
| 1.5 | 13.2 | 94.9 | 2.59 | 0.91 | 38.9 | 81.7 | ||
| S ≥ 3 | 0.799 | 0.69 | 86.4 | 66.9 | 2.58 | 0.2 | 19.4 | 98.2 |
| GPR | ||||||||
| S ≥ 2 | 0.714 | 0.217 | 86.5 | 44.7 | 1.56 | 0.30 | 27.3 | 93.3 |
| S ≥ 3 | 0.801 | 0.374 | 73.9 | 72.8 | 2.71 | 0.36 | 20.2 | 96.8 |
| RPR | ||||||||
| S ≥ 2 | 0.643 | 0.090 | 70.7 | 60.4 | 1.79 | 0.49 | 29.7 | 89.7 |
| S ≥ 3 | 0.705 | 0.098 | 73.1 | 67.5 | 2.25 | 0.40 | 17.4 | 96.4 |
APRI, aspartate transaminase to platelet ratio index; FIB‐4, fibrosis index based on the 4 factors; GPR, gamma‐glutamyl transpeptidase to platelet ratio index; NLR, negative likelihood ratio; NPV, negative predictive value; PLR, positive likelihood ratio; PPV, positive predictive value; RPR, red cell volume distribution width‐to‐platelet ratio.